Product Description: Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14(1):132.
Molecular Weight: 151000 (average)
Compound Purity: 98.15
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antibody-Drug Conjugates (ADCs);Apoptosis
English
Deutsch
